7th EPLS – Speaker Details

Frederic Desdouits

EVP Head of Corporate Business Development, Acquisitions & Market Intelligence

Pierre Fabre

Frederic Desdouits is head of Pierre Fabre Group Business Development, Acquisition and Market Intelligence. He is a member of Pierre Fabre Pharmaceuticals board of directors and Pierre Fabre Products Development Committee. Prior to join Pierre Fabre, Frederic was a Managing Partner at Bionest Partners, a consulting and transaction firm based in Paris and New York specialized in healthcare and biotechnology; and the founder Managing Partner of Bionest Partners Finance, a boutique specialized in value strategy and fund raising for emerging bio-companies. Before becoming an entrepreneur, Frederic was a partner in charge of Pharmaceutical and Biotechnology sectors at Exane BNP-Paribas, an investment company. Before heading for finance, Frederic work in research for GlaxoWellcome in France (now GSK), as a consultant for Hoechst in the USA and as a PhD student at Rhône-Poulenc in France (now Sanofi).

Frederic is graduated from Ecole Polytechnique (Palaiseau, France), obtained a MS in pharmacology, a PhD in Neurosciences in Jacques Glowinski’s laboratory (Paris 6 University, France), did a post-doc at the Rockefeller University in Paul Greengard’s laboratory (New York, USA) and is a CEFA (Certified European Financial Analyst).

Reiner Christensen

President

Chameleon Pharma Consulting

Reiner Christensen looks back to more than 20 years of substantial experience in OTC, food supplements and Rx. products in General Management.

He has worked in the Latin American, CIS/CEE, Asian and European Region.

His focus is on Strategy, Marketing, Business Development and M&A.

Reiner is German. He holds a Diploma in Industrial Engineering & Management (Dipl. Wirtschaftsingenieur) and an Executive MBA from Ashridge.

Manuela Mueller-Gerndt

IBM DACH Smarter Healthcare

Manuela Mueller-Gerndt is the Industry Leader of Healthcare & Pharma Life Sciences at IBM DACH. In this position she heads up IBM’s healthcare business including the healthcare solution strategy and execution. Her clients include university hospitals, large private owned hospital chains, public and private healthcare insurance organizations, medical technology companies, pharma / life science organizations as well the Ministry of Health.

Manuela has worked in the Healthcare Industry for 15 years, including serving for two years as Vice President for Ziehm Imaging GmbH, an innovative medical imaging company where she led the turnaround team and was in charge for strategic product innovations, marketing and education. Manuela started her career at Siemens Medical Solutions.

Manuela holds a degree in business administration from the Universities in Munich and Rome. She followed her executive and healthcare technology education at Duke University, M.I.T., Cambridge and Boston University (USA), published books and publications in German, English and Chinese language.

Burkhard Sträter

Sträter Life Sciences GmbH

Prof. Burkhard Sträter studied law in Marburg, Münster and Berlin starting his career as a Local Court Judge in Berlin-Tiergarten in 1977. In 1981 he was appointed Government Director, Head of Section for Matters of Law and General Policy of the Federal Health Agency and since 1997 he has practiced as a Lawyer in Bonn. In addition Prof. Burkhard Sträter has been a Lecturer at the Administrative Academy of Berlin -public law [1980-1984] and since 1985 has engaged in advanced training of scientists from the pharmaceutical industry on regulatory, pharmaceutical law and social law issues associated with the development, manufacture, marketing authorisation and marketing of medicinal products and medical devices. More recently he was awarded an honorary professorship at the Rheinische Friedrich-Wilhelms-University of Bonn, Chair of the Master Study Course on Drug Regulatory Affairs MDRA, and since 2010 he lectures at the Westfälische Wilhelms-University of Muenster on the “Medical Law” masters course

Prof. Burkhard Sträter is a member of Deutsche Gesellschaft für Regulatory Affairs e. V. (DGRA – German Society of Regulatory Affairs) and the Working Group of the German Federation for Medical Technology (Bundesverband Medizintechnologie).

Rafael Cabrera

Director Business Development and Market Access

UCB Iberia

Pharmacist and Master in Health Economics with 30 years of experience in the Pharmaceutical and Biotech Industry, in Business Development, Regulatory Affairs and Market Access

Monique Martin

Vice-President and General Manager, HEOR Operations Europe

Optum

Monique Martin, M.B.A., M.Sc. PharmD, joined the European office of Optum, a global consultancy company specialized in HEOR, Late Phase research and real world data, in June 2002 and is currently Vice-President and General Manager of Optum’s European HEOR Operations. A qualified pharmacist, Monique gained her Masters degrees in Health Economics from City University, London, and in Pharmacology from the University of Amsterdam. She further holds, an M.B.A. from the Rotterdam School of Management and an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine. Her previous career in the pharmaceutical industry included spells as a manager in health economics at the Swiss headquarters of Serono and at Mundipharma in the UK, where she held health economics and licensing responsibilities.

Charlie Alexander

Senior Director Business Development

Shire Pharmaceuticals

Charlie has been at Shire for 8 years. His primary objective is in-licensing. During his time at Shire his therapeutic focus has altered from renal to anti-infectives and most recently haematology. In his time at Shire he has also supported M&A efforts and Shire’s goal to expand geographically. Most notably Charlie concluded a collaboration deal with Shionogi to bring Shire’s successful ADHD portfolio to Japan. Prior to Shire he held positions at Apex Healthcare Consulting, Xenova and GSK where his remits varied from out-licensing to commercial strategy and marketing.

Chris Adams

CEO

Cydan Development

Chris Adams has more than 20 years of business development, transactional and commercial planning experience in orphan drug development as well as a successful track record in private and public biotech fund raising.

Prior to joining Cydan, Dr. Adams was President of CMA Biotech Consulting where he worked in an advisory role for a number of development stage orphan drug companies. Previously, Dr. Adams was Chief Business Officer of FoldRx Pharmaceuticals Inc., where he was responsible for business strategy, licensing and business development. He led the M&A process, which resulted in the acquisition of the company by Pfizer in October of 2010. Prior to FoldRx, Dr. Adams was Senior Vice President, Business Development for ViaCell Inc., and Vice President, Business Development for Transkaryotic Therapies Inc. Previously, Dr. Adams served Director of Business Development for the Pharmaceutical Division of Ciba-Geigy Limited, Basel, Switzerland.

Dr. Adams has a diploma in organic chemistry and biochemistry and a PhD in organic chemistry from the University of Zurich. Dr. Adams also holds an MBA from INSEAD of Fontainebleau, France.